Skip to main content

Table 4 Population characteristics of the involved studies

From: Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors

Study

Combi-AD [32]

EORTC-19071 [18]

Checkmate-238 [33]

Branch

Dab + Tram

Placebo

Ipilimumab

Placebo

Nivolumab

Ipilimumab

Number of Patients

438

432

475

476

453

453

Gender (Male)

44.5

44.7

62.3

61.6

57.0

59.4

Age: Median, Range

50 (18–89)

51 (20–85)

51 (20–84)

52 (18–78)

56 (19–83)

54 (18–86)

Proportion < 65 years

Not reported

82.9

81.7

73.5

74.8

Disease Stage

 IIIa (%)

18.9

16.4

20.6

20.6

 IIIb (%)

38.6

43.3

38.3

38.2

36.0

32.7

 IIIc (%)

41.3

38.4

25.7

25.4

45.0

48.1

 III (Not Specified, %)

1.1

1.9

    

 IV (%)

  

15.4

15.8

18.1

19.2

 Not Reported

  

1.0

Stage III lymph node involvement

 Microscopic (%)

34.7

36.3

44.2

40.5

33.9

36.6

 Macroscopic (%)

36.1

37.3

55.8

49.5

59.3

58.5

 Not Reported

29.2

26.4

6.8

4.9

  1. Dab+Tram dabrafenib/trametinib combination therapy. Sum of percentages may deviate from 100% due to rounding errors